Casirivimab and imdevimab: Cost-effectiveness analysis of the treatment based on monoclonal antibodies on outpatients with Covid-19.

Matteo Ruggeri,Alessandro Signorini,Silvia Caravaggio

PloS one（2023）

引用 2|浏览1

暂无评分

摘要

The administration of casirivimab and imdevimab in outpatients with Covid-19 can accelerate recovery from the disease for patients, make hospital resource management more efficient and significantly reduce costs for healthcare facilities.

查看译文

关键词

casirivimab,monoclonal antibodies,imdevimab,cost-effectiveness

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要